Clinical Trials
13 trialsNCT03721744 2024-04-03
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
Phase 2/3 Unknown
NCT00997906 2022-09-29
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
National Cancer Centre, Singapore
Phase 2/3 Unknown
NCT05213312 2022-06-15
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Shanghai Zhongshan Hospital
Phase 2/3 Unknown
NCT05189067 2022-01-12
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Unknown
NCT02065687 2021-09-30
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
GOG Foundation
Phase 2/3 Unknown
NCT03580395 2021-07-09
Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Unknown
NCT04753177 2021-02-15
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Phase 2/3 Unknown
NCT04435652 2020-06-17
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT02279134 2020-04-03
Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma
ChineseAMS
Phase 2/3 Unknown
NCT02741856 2018-10-25
SCOPE2
Velindre NHS Trust
Phase 2/3 Unknown
NCT00689715 2016-07-26
EUS-EP
Asan Medical Center
Phase 2/3 Unknown
NCT02159820 2014-06-10
DAC and CT
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT00003643 2012-03-06
Combination Chemotherapy in Treating Men With Germ Cell Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Unknown